Tyvaso Dosing and Titration Evaluation: TyTRATE Registry

A Patient Registry to Observe the Real-World Dosing and Titration of Tyvaso®

Status

Completed

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT01799473

Enrollment

Registered

2013-02-26

Start date

2013-01-31

Completion date

2014-12-31

Last updated

2015-03-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Pulmonary Arterial Hypertension

Keywords

Tyvaso, PAH

Brief summary

This prospective, observational, multi-center, patient registry will follow patients who are newly initiated on Tyvaso for the treatment of Pulmonary Arterial Hypertension (PAH). Once enrolled, the patients' dose and titration will be followed for the first 6 months of treatment with Tyvaso. A call-center will contact the patients directly at weeks 1, 2, 3, 4, 8, 12, 16, 20, and 24 to review their dose and titration schedule. In addition to patient-reported dosing data, some patient demographic information, will be collected by the investigative site at Baseline.

Interventions

None listed

Study design

Observational model

COHORT

Time perspective

PROSPECTIVE

Eligibility

Sex/Gender

ALL

Healthy volunteers

Inclusion criteria

* Are newly prescribed Tyvaso for the treatment of PAH and plan to initiate therapy * Are willing and able to be contacted by the patient call center.

Exclusion criteria

* Have previously received Tyvaso. * Are currently enrolled in an interventional (non-FDA approved) PH clinical trial.

Design outcomes

Primary

Measure	Time frame
Observe dose changes of Tyvaso over time	6 Months

Countries

Puerto Rico, United States

Outcome results